Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ME2 | P23368 | 2/20 | 0.50 |
| ▸ | ME1 | P48163 | 2/20 | 0.50 |
| ▸ | ME3 | Q16798 | 2/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12206736 | 1.00 | MAPT (0.58) | MAPTGAANPC1KDM4EPOLB | |
| SCHEMBL2306481 | 0.91 | MAPT (0.65) | MAPTGAANPC1KDM4EPOLB | |
| SCHEMBL2313406 | 0.87 | MAPT (0.58) | MAPTGAANPC1KDM4EPOLB | |
| SCHEMBL2309047 | 0.83 | MAPT (0.54) | MAPTGAANPC1KDM4EPOLB | |
| SCHEMBL12206665 | 0.82 | MAPT (0.60) | MAPTGAANPC1KDM4EPOLB | |
| SCHEMBL12206652 | 0.80 | KMT2A (0.65) | MAPTNPC1KDM4EPOLBRAB9A | |
| SCHEMBL12206707 | 0.80 | KMT2A (0.65) | MAPTNPC1KDM4EPOLBRAB9A | |
| SCHEMBL2309885 | 0.80 | MAPT (0.59) | MAPTGAANPC1KDM4EPOLB | |
| SCHEMBL12206689 | 0.80 | MAPT (0.59) | MAPTGAANPC1KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL2309495 | 0.79 | ME2 (0.58) | MAPTGAANPC1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| WO-2010028776-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-18 | — | — | WO | disclosed |
| EP-2163541-A1 | Piperazine derivatives for binding and imaging amyloid plaques and their use | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | APP, APBA1, PSEN1 | MAPT 14/4885GAA 2063/4885NPC1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.